RESUMO
BACKGROUND: Selecting the appropriate antithrombotic regimen for patients with atrial fibrillation (AF) who have undergone percutaneous coronary intervention (PCI) or have had medically managed acute coronary syndrome (ACS) remains complex. This multi-centre observational study evaluated patterns of antithrombotic therapies utilized among Canadian patients with AF post-PCI or ACS. METHODS AND RESULTS: By retrospective chart audit, 611 non-valvular AF patients [median (interquartile range) age 76 (69-83) years, CHADS2 score 2 (1-3)] who underwent PCI or had medically managed ACS between August 2018 and December 2020 were identified by 68 cardiologists across eight provinces in Canada. Overall, triple antithrombotic therapy [TAT: combined oral anticoagulation (OAC) and dual antiplatelet therapy (DAPT)] was the most common initial antithrombotic strategy, with use in 53.8â¯% of patients, followed by dual pathway therapy (32.7â¯% received OAC and a P2Y12 inhibitor, and 4.1â¯% received OAC and aspirin) and DAPT (9.3â¯%). Median duration of TAT was 30 (7, 30) days. Compared to the previous CONNECT AFâ¯+â¯PCI-I program, there was an increased use of dual pathway therapy relative to TAT over time (P-value <.0001). DOACs (direct oral anticoagulants) represented 90.3â¯% of all OACs used overall, with apixaban being the most utilized (50.5â¯%). Proton pump inhibitors were used in 57.0â¯% of all patients, and 70.1â¯% of patients on ASA. Planned antithrombotic therapies at 1â¯year were: 76.2â¯% OAC monotherapy, 8.3â¯% OACâ¯+â¯ASA, 7.9â¯% OACâ¯+â¯P2Y12 inhibitor, 4.3â¯% DAPT, 1.3â¯% ASA alone, and <1â¯% triple therapy. CONCLUSION: In accordance with recent Canadian Cardiovascular Society guideline recommendations, we observed an increased use of dual pathway therapy relative to TAT over time in both AF patients post-PCI (elective and emergent) and in those with medically managed ACS. Additionally, DOACs have become the prevailing form of anticoagulation across all antithrombotic regimens. Our findings suggest that Canadian physicians are integrating evidence-based approaches to optimally manage the bleeding and thrombotic risks of AF patients post-PCI and/or ACS.
Assuntos
Fibrilação Atrial , Doença da Artéria Coronariana , Intervenção Coronária Percutânea , Humanos , Idoso , Inibidores da Agregação Plaquetária/efeitos adversos , Fibrilação Atrial/complicações , Fibrilação Atrial/tratamento farmacológico , Doença da Artéria Coronariana/complicações , Doença da Artéria Coronariana/terapia , Anticoagulantes/efeitos adversos , Fibrinolíticos/uso terapêutico , Intervenção Coronária Percutânea/efeitos adversos , Estudos Retrospectivos , Canadá , AspirinaRESUMO
INTRODUCTION: In patients with heart failure (HF) and reduced ejection fraction, increased heart rate (HR) is an independent risk factor for adverse outcomes. In systolic HF treatment with the If inhibitor ivabradine trial (SHIFT), Ivabradine improved survival when added to conventional treatment including ß-blockers. However, the extent of benefit in the real world is unclear. We examined the characteristics of patients on guideline-directed therapy and determined who had SHIFT-like characteristics. METHODS: A total of 1096 patients with chronic HF were reviewed from June 2014 to April 2015 in two HF clinics in Toronto: an academic institution (AI), and a community hospital (CH) clinic. SHIFT-like characteristics [left ventricular ejection fraction (LVEF) ≤35%; sinus rhythm; and HR ≥ 70 bpm] were described. RESULTS: For all patients, mean age was 75 ± 13 years, overall LVEF was 44 ± 15%, AI less than CH (41.9 ± 14.0% vs. 45.7 ± 15.0%; p < 0.0001). More than two-thirds of patients in both groups were on ß-blockers; with less than one-third at target dose. The proportion of patients with SHIFT-like characteristics was 8.4% AI and 11.7% CH, respectively (p = 0.0658). CONCLUSION: In HF clinics from both academic and community hospitals in Toronto, up-titration in the dose of ß-blockers and other guideline therapy can be improved on. A small proportion of patients with HF and SHIFT-like characteristics may potentially benefit from the addition of Ivabradine, just approved in Canada; this number will be further reduced if target dosage for ß-blockers is achieved. FUNDING: Servier Inc.
Assuntos
Centros Médicos Acadêmicos , Antagonistas Adrenérgicos beta/uso terapêutico , Benzazepinas/uso terapêutico , Insuficiência Cardíaca/tratamento farmacológico , Hospitais Comunitários , Antagonistas Adrenérgicos beta/administração & dosagem , Idoso , Idoso de 80 Anos ou mais , Benzazepinas/administração & dosagem , Canadá , Doença Crônica , Quimioterapia Combinada , Feminino , Frequência Cardíaca/fisiologia , Humanos , Ivabradina , Masculino , Pessoa de Meia-Idade , Fatores de Risco , Volume Sistólico/fisiologia , Resultado do TratamentoRESUMO
BACKGROUND: The postdischarge rehospitalization and death rates are high in patients with acute heart failure (HF) syndromes despite optimization of standard therapy for chronic HF. To the best of our knowledge, there has been no systematic analysis of the causes of death and rehospitalization in this patient population. METHODS: This was a prespecified analysis of adjudicated cause-specific all-cause mortality and cardiovascular (CV) hospitalization in the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) trial, a randomized, double-blind, placebo-controlled study in patients hospitalized with worsening HF and left ventricular ejection fraction < or =40% comparing tolvaptan, an oral vasopressin receptor antagonist to placebo, in addition to standard care. RESULTS: Of the 4,133 randomized, there were 5,239 rehospitalizations and 1,080 deaths during a median of 9.9 months. Of all deaths, 41.0% were due to HF, 26.0% due to sudden cardiac death (SCD), 2.6% due to acute myocardial infarction (MI), 2.2% due to stroke, and 13.2% due to non-CV causes. Of all hospitalizations, 39.2% were non-CV, whereas 46.3% were for HF, and a minority of hospitalizations was due to stroke, MI, arrhythmia, or other CV causes. CONCLUSIONS: Despite close follow-up and evidence-based therapy within a clinical trial, rehospitalization and death remain high. Although most deaths were from HF, one quarter of patients had SCD. In addition, there were almost as many non-CV hospitalizations as HF hospitalizations. Knowledge of the causes of death and rehospitalization may be essential for proper management and early initiation of therapy.
Assuntos
Antagonistas dos Receptores de Hormônios Antidiuréticos , Fármacos Cardiovasculares/uso terapêutico , Insuficiência Cardíaca/tratamento farmacológico , Insuficiência Cardíaca/mortalidade , Readmissão do Paciente/estatística & dados numéricos , Idoso , Idoso de 80 Anos ou mais , Benzazepinas/uso terapêutico , Causas de Morte , Feminino , Insuficiência Cardíaca/fisiopatologia , Humanos , Masculino , Pessoa de Meia-Idade , Volume Sistólico , TolvaptanRESUMO
Focal epithelial hyperplasia is a benign, papulo-nodular disease of the oral cavity. It is rare, affecting primarily Native American populations during childhood. It is closely associated with human papillomavirus 13 and 32. This report describes the diagnosis of 2 cases of focal epithelial hyperplasia in children from southern Guyana. The diagnosis was made using clinical criteria, polymerase chain reaction, and DNA sequencing.
Assuntos
Alphapapillomavirus/isolamento & purificação , Hiperplasia Epitelial Focal/virologia , Infecções por Papillomavirus/virologia , Alphapapillomavirus/genética , Criança , DNA Viral/análise , Feminino , Hiperplasia Epitelial Focal/diagnóstico , Hiperplasia Epitelial Focal/patologia , Guiana , Humanos , Masculino , Infecções por Papillomavirus/diagnóstico , Infecções por Papillomavirus/patologia , Reação em Cadeia da PolimeraseRESUMO
A pseudoaneurysm of a saphenous vein bypass graft to a first diagonal coronary artery is reported. The patient presented with worsening angina symptoms 14 years after her first bypass surgery when this diagonal graft was implanted. Angiography revealed a 3 x 3 cm pseudoaneurysm of the graft. The perforation site was successfully occluded by two overlapping polytetrafluoroethylene (PTFE)-covered JoStents.